NZ516026A - Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents - Google Patents

Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents

Info

Publication number
NZ516026A
NZ516026A NZ516026A NZ51602698A NZ516026A NZ 516026 A NZ516026 A NZ 516026A NZ 516026 A NZ516026 A NZ 516026A NZ 51602698 A NZ51602698 A NZ 51602698A NZ 516026 A NZ516026 A NZ 516026A
Authority
NZ
New Zealand
Prior art keywords
taxane
human patients
administered
oral
bioavailability
Prior art date
Application number
NZ516026A
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of NZ516026A publication Critical patent/NZ516026A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood or plasma levels are disclosed, wherein the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A; and a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also disclosed, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.
NZ516026A 1997-05-27 1998-04-22 Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents NZ516026A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27
NZ50112798 1998-04-22

Publications (1)

Publication Number Publication Date
NZ516026A true NZ516026A (en) 2003-06-30

Family

ID=26652133

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ516026A NZ516026A (en) 1997-05-27 1998-04-22 Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents

Country Status (1)

Country Link
NZ (1) NZ516026A (en)

Similar Documents

Publication Publication Date Title
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
CA2290446A1 (en) Method and compositions for administering taxanes orally to human patients
HK1001960A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CZ309247B6 (en) 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in treating a solid tumour
NO20014842L (en) Docet shaft in combination with rhuMAb HER2 for the treatment of cancer
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
RU2012106620A (en) COMBINATIONS AND METHODS OF INTRODUCING THERAPEUTIC MEDICINES AND COMBINED THERAPY
RU2002127804A (en) MEDICINAL SYSTEM FOR TREATMENT OF COMPLICATIONS CONNECTED WITH DIABETES AND NEUROPATHY, AND THEIR APPLICATION
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
CO5251425A1 (en) METHOD AND COMPOSITIONS TO ADMINISTER TAXANS ORALLY TO HUMAN PATIENTS
WO1999040883A3 (en) Compositions and methods for the treatment of cystic fibrosis
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
RU95101385A (en) Products containing g-csf and tnf-binding protein
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
RU99128033A (en) METHOD AND COMPOSITIONS FOR ORAL IMPLEMENTATION OF TAXANS
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer
RO116771B1 (en) Method for preventing or treating the addiction on, tolerance or abuse of benzodiazepines
CA2313270A1 (en) Use of deferiprone in treating and preventing iron-induced cardiac disease
WO2002064214A8 (en) Anti cancer combination of substituted pyrroles and paclitaxel
NZ516026A (en) Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents
CA2480275A1 (en) Statin therapy for enhancing cognitive maintenance
CA2368352A1 (en) Method for treating neurodegeneration
UA30251A (en) The method for treatment of oddis sphincter hypertonia for patients with chronic acalculous cholecystitis along with hypersympathicotonia
RU98114855A (en) USE OF THE 1-ENANTIOMER OF CENTRHROMAN TO OBTAIN A PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF BREAST CANCER

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)